BBLG.NASDAQBone Biologics CORP
10-K: Bone Biologics Reports 2024 Financial Results and Provides Business Update
Sentiment:
Annual Results
Bone Biologics Corporation reports its financial results for the year ended December 31, 2024, highlighting ongoing clinical trials and financial activities.
Capital raiseThe company completed a public offering in March 2024, generating net proceeds of $1.5 million.The company completed a warrant inducement in August 2024, generating net proceeds of $1.8 million.The company has an active ATM facility with H.C. Wainwright & Co., LLC, and sold shares for net proceeds of $1.1 million during 2024.The company will continue to attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital.
Worse than expectedThe company reported a net loss of $4.1 million and the auditor expressed substantial doubt about the company's ability to continue as a going concern.
Summary
- Bone Biologics Corporation is focused on bone regeneration in spinal fusion using NELL-1 protein.
- The company's lead product, NB1, is undergoing a pilot clinical study in Australia to evaluate its safety and effectiveness in treating degenerative disc disease.
- The company incurred a net loss of $4.1 million for the year ended December 31, 2024, and used $4.1 million in operating activities.
- As of December 31, 2024, the company's cash balance was $3.3 million, expected to fund operations into the fourth quarter of 2025.
- The company completed several financing activities during 2024, including a public offering and an ATM facility, generating net proceeds of $4.4 million.
- The company is subject to an exclusive license agreement with UCLA TDG, requiring milestone payments and royalties.
- The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
- The company is subject to various healthcare laws and regulations, including anti-kickback and false claims laws.
- The company is subject to a formal code of ethics and an insider trading policy.
Sentiment
Score: 4
Explanation: The document presents a mixed sentiment. While there is progress in clinical trials and capital raising, the significant net loss and going concern warning from the auditor weigh heavily on the overall outlook.
Positives
- The company is progressing with its pilot clinical study of NB1 in Australia.
- The company successfully raised capital through public offerings and an ATM facility.
- The company has an exclusive license agreement with UCLA TDG for NELL-1 technology.
- The company has a comprehensive intellectual property portfolio covering NELL-1 manufacture, compositions, and uses.
- The company has a formal code of ethics and an insider trading policy.
Negatives
- The company incurred a net loss of $4.1 million for the year ended December 31, 2024.
- The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
- The company is dependent on raising additional capital to fund its operations.
- The company is subject to an exclusive license agreement with UCLA TDG, requiring milestone payments and royalties.
- The company is subject to various healthcare laws and regulations, including anti-kickback and false claims laws.
Risks
- The company's limited operating history makes it difficult to evaluate its current business and future prospects.
- The company's long-term capital requirements are subject to numerous risks.
- The company's recurring operating losses have raised substantial doubt regarding its ability to continue as a going concern.
- The company's product candidates are at an early stage of development and may not be successfully developed or commercialized.
- The company is dependent on third parties for raw materials, manufacturing, and clinical trials.
- The company may infringe the intellectual property rights of others.
- The company's commercial success depends on attaining significant market acceptance of its lead product candidate.
- The company operates in a highly competitive environment.
- The company is subject to healthcare compliance regulations.
- The price of the company's common stock may fluctuate substantially.
Future Outlook
The company expects to continue investing in development activities for NELL-1 and will attempt to raise additional capital to fund future operations.
Industry Context
The orthobiologic and orthopedic industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property, with competition from large established orthopedic companies such as Medtronic, Stryker, Globus Medical, and DePuy-Synthes.
Comparison to Industry Standards
- The document does not provide enough information to make a detailed comparison to industry standards.
- Without specific financial benchmarks or project milestones from comparable companies, a direct assessment is not possible.
- A thorough analysis would require comparing Bone Biologics' clinical trial progress, regulatory submissions, and financial metrics against similar companies in the bone regeneration and spinal fusion market.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Don Hankey | Phillip Meikle | 2024-10-16 | Don Hankey's resignation |
Stakeholder Impact
- Shareholders face the risk of dilution from future equity offerings.
- Employees face uncertainty due to the company's going concern status.
- Customers (spine surgeons and patients) may benefit from the potential success of NB1.
- Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.
Next Steps
- Continue the pilot clinical study of NB1 in Australia.
- Prepare for a potential larger U.S. pivotal clinical study.
- Seek additional capital through debt and/or equity financing.
- Continue development activities for NELL-1.
Key Dates
| Date | Description |
|---|---|
| 2004-09-09 | Bone Biologics, Inc. was incorporated in California. |
| 2006-03-15 | Effective date of the Exclusive License Agreement between the Company and UCLA TDG. |
| 2007-10-18 | AFH Acquisition X, Inc. was incorporated in Delaware. |
| 2014-09-19 | Date of the Merger Agreement among AFH Acquisition X, Inc., Bone Biologics Acquisition Corp., and Bone Biologics, Inc. |
| 2014-09-22 | The Company changed its name to Bone Biologics Corporation. |
| 2017-06-19 | Date of the Amended and Restated Exclusive License Agreement between the Company and UCLA TDG. |
| 2019-04-09 | Effective date of the Amended License Agreement with UCLA TDG. |
| 2021-12-17 | Date of the employment agreement between the Company and Deina Walsh. |
| 2022-01-03 | Effective date of the employment agreement between the Company and Deina Walsh. |
| 2023-06-05 | Effective date of the 1-for-30 reverse stock split. |
| 2023-12-20 | Effective date of the 1-for-8 reverse stock split. |
| 2024-01-01 | Effective date of the amended and restated letter agreement with Jeffrey Frelick. |
| 2024-01-08 | Robert Gagnon appointed to the Board of Directors. |
| 2024-03-06 | The Company sold 119,000 shares of common stock together with warrants to purchase 119,000 shares of common stock. |
| 2024-08-02 | Existing warrants to purchase 781,251 shares of common stock issued in March 2024, were exercised for cash at the exercise price of $2.43 per share. |
| 2024-09-27 | The Company entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. |
| 2024-10-01 | Don Hankey resigned from the Board of Directors. |
| 2024-10-16 | Phillip Meikle appointed to the Board of Directors. |
| 2024-12-13 | The Company filed a prospectus supplement increasing the aggregate offering price that can be sold under the ATM Agreement by $535,176. |
| 2025-01-17 | Mr. Frelick and Ms. Walsh received stock option grants for 2024 bonus achievements. |
| 2025-02-19 | As of this date, there were 3,271,042 shares of common stock outstanding. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.